Home/Filings/4/0001470831-25-000297
4//SEC Filing

DANIELS RONALD J 4

Accession 0001470831-25-000297

CIK 0001743881other

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 6:03 PM ET

Size

481.9 KB

Accession

0001470831-25-000297

Insider Transaction Report

Form 4
Period: 2025-11-06
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-0661,03130,523 total
    Exercise: $34.65Exp: 2030-02-11Common Stock (61,031 underlying)
  • Sale

    Common Stock

    2025-11-06$63.72/sh61,031$3,888,99916,991 total
  • Exercise/Conversion

    Common Stock

    2025-11-06$34.65/sh+61,031$2,114,72478,022 total
Footnotes (2)
  • [F1]Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F2]The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother
IncorporatedOntario, Canada

Related Parties

1
  • filerCIK 0001164475

Filing Metadata

Form type
4
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 6:03 PM ET
Size
481.9 KB